Faeth Therapeutics Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The Company's lead program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer. Faeth Therapeutics Inc., formerly known as Sensei Biotherapeutics Inc., is based in AUSTIN, Texas.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-21.08M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 5.12 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -1012.17% |
| Return on Assets (Trailing 12 Months) | -175.69% |
| Current Ratio (Most Recent Fiscal Quarter) | 19.69 |
| Quick Ratio (Most Recent Fiscal Quarter) | 19.69 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $14.74 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-2.84 |
| Earnings per Share (Most Recent Fiscal Year) | $-16.72 |
| Diluted Earnings per Share (Trailing 12 Months) | $-141.65 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 25.84M |
| Free Float | 24.03M |
| Market Capitalization | $884.78M |
| Average Volume (Last 20 Days) | 0.30M |
| Beta (Past 60 Months) | -0.28 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 7.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 10.50% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |